A detailed history of Sovereign Financial Group, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Sovereign Financial Group, Inc. holds 3,379 shares of ABBV stock, worth $580,275. This represents 0.16% of its overall portfolio holdings.

Number of Shares
3,379
Previous 3,503 3.54%
Holding current value
$580,275
Previous $600,000 11.17%
% of portfolio
0.16%
Previous 0.15%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$163.84 - $199.33 $20,316 - $24,716
-124 Reduced 3.54%
3,379 $667,000
Q2 2024

Jul 15, 2024

BUY
$154.79 - $180.76 $45,043 - $52,601
291 Added 9.06%
3,503 $600,000
Q1 2024

Apr 15, 2024

BUY
$159.82 - $182.1 $80,389 - $91,596
503 Added 18.57%
3,212 $584,000
Q4 2023

Feb 06, 2024

SELL
$137.6 - $154.97 $46,921 - $52,844
-341 Reduced 11.18%
2,709 $419,000
Q3 2023

Nov 03, 2023

SELL
$133.59 - $154.65 $2,271 - $2,629
-17 Reduced 0.55%
3,050 $454,000
Q2 2023

Jul 31, 2023

SELL
$132.51 - $164.9 $795 - $989
-6 Reduced 0.2%
3,067 $413,000
Q1 2023

May 04, 2023

BUY
$144.61 - $166.54 $1,590 - $1,831
11 Added 0.36%
3,073 $489,000
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $199,719 - $239,516
1,444 Added 89.25%
3,062 $495,000
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $1,610 - $1,847
-12 Reduced 0.74%
1,618 $217,000
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $2,890 - $3,674
-21 Reduced 1.27%
1,630 $250,000
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $2,639 - $3,275
20 Added 1.23%
1,651 $268,000
Q4 2021

Feb 15, 2022

BUY
$107.43 - $135.93 $175,218 - $221,701
1,631 New
1,631 $221,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $304B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Sovereign Financial Group, Inc. Portfolio

Follow Sovereign Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sovereign Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sovereign Financial Group, Inc. with notifications on news.